SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-22-005982
Filing Date
2022-04-22
Accepted
2022-04-22 08:27:32
Documents
9
Period of Report
2022-06-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A alxo-def_14a-2022_proxy.htm DEF 14A 1722847
2 GRAPHIC img247672129_0.jpg GRAPHIC 7391
3 GRAPHIC img247672129_1.jpg GRAPHIC 4688
4 GRAPHIC img247672129_2.jpg GRAPHIC 4028
5 GRAPHIC img247672129_3.jpg GRAPHIC 4028
6 GRAPHIC img247672129_4.jpg GRAPHIC 13435
7 GRAPHIC img247672129_5.jpg GRAPHIC 15046
8 GRAPHIC img247672129_6.jpg GRAPHIC 120691
9 GRAPHIC img247672129_7.jpg GRAPHIC 122270
  Complete submission text file 0000950170-22-005982.txt   2126479
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

IRS No.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39386 | Film No.: 22843503
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences